Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) – 2020 to 2025

$3,850.00$5,850.00

Published on: March 17, 2020
Clear
SKU: GMS-2020 Category:

OVERVIEW

The global market for PDX models is expected to reach USD 256.9 million by 2025, rising over the forecast period to a CAGR of 15.45%. The overall growth of the Patient Driven Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous public and private sector funding for cancer research, and growth in the number of pharmaceutical industry R&D activities.

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 1

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 2

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 3

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 4

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 5

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 6

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 7

Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) - 2020 to 2025 8

TABLE OF CONTENT

1 Global Patient Derived Xenograft/PDX Models Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Patient Derived Xenograft/PDX Models Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Patient Derived Xenograft/PDX Models Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Patient Derived Xenograft/PDX Models Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Patient Derived Xenograft/PDX Models Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Patient Derived Xenograft/PDX Models Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Patient Derived Xenograft/PDX Models Market – By Type (Market Size – &
million/billion)
8.1 Mice Models
8.2 Rat Models

9 Global Patient Derived Xenograft/PDX Models Market – By Tumor Type
9.1 Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
9.2 Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
9.3 Gynecological Tumor Models (breast, ovarian, and cervical tumors)
9.4 Hematological Tumor Models (leukemia and lymphoma)
9.5 Urological Tumor Models (renal, prostate, and bladder tumors)
9.6 Other

10 Global Patient Derived Xenograft/PDX Models Market – By Application
10.1 Pre-clinical Drug Development and Basic Cancer Research
10.2 Biomarker Analysis

11 Global Patient Derived Xenograft/PDX Models Market – By End User
11.1 Pharmaceutical & Biotechnology Companies
11.2 Contract Research Organizations
11.3 Academic & Research Institutions

12 Global Patient Derived Xenograft/PDX Models Market – By Geography (Market Size – &
million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Patient Derived Xenograft/PDX Models Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Patient Derived Xenograft/PDX Models Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 Crown Bioscience Inc.
14.3 The Jackson Laboratory
14.4 Champions Oncology, Inc.
14.5 Pharmatest Services Ltd.
14.6 Hera Biolabs
14.7 Charles River Laboratories International, Inc.
14.8 ONCODESIGN
14.9 Horizon Discovery Group PLC (Sage Labs, Inc.)
14.10 EPO Berlin-Buch GmbH
14.11 WuXi Apptec (Group of Subsidiaries Under WuXi Pharmatec)
14.12 Company 11 & more

15 Global Patient Derived Xenograft/PDX Models Market – Appendix
15.1 Sources
15.2 Abbreviations